OTCMKTS:BIOYF BioSyent (BIOYF) Stock Price, News & Analysis $11.97 +0.09 (+0.76%) As of 10/9/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendNews and Trends About BioSyent Stock (OTCMKTS:BIOYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioSyent alerts:Sign Up Key Stats Today's Range$11.89▼$11.9750-Day Range$10.47▼$12.4152-Week Range$7.63▼$12.41Volume880 shsAverage Volume2,435 shsMarket CapitalizationN/AP/E Ratio58.82Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioSyent Inc. is a Canadian specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing pharmaceutical and healthcare products. Through its operating business, BioSyent Pharma Inc., the company targets products that address therapeutic and consumer health needs in the Canadian market. BioSyent’s portfolio includes FeraMAX, a line of oral iron replacement products available in formulations such as FeraMAX 150 and FeraMAX Powder. The company’s business model emphasizes building and supporting established brands through regulatory, sales, marketing and distribution activities rather than manufacturing a broad range of pharmaceutical products. BioSyent is headquartered in Canada and primarily serves Canadian patients, healthcare professionals and consumers. The company has expanded its portfolio over time through product acquisitions and licensing arrangements, although its product offerings and business activities may change as new agreements are completed.AI Generated. May Contain Errors. Read More BioSyent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreBIOYF MarketRank™: BioSyent scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BioSyent. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioSyent is 58.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.73.Price to Earnings Ratio vs. SectorThe P/E ratio of BioSyent is 58.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.13.Read more about BioSyent's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverBioSyent has a short interest ratio ("days to cover") of 3.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioSyent has recently decreased by 41.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioSyent does not currently pay a dividend.Dividend GrowthBioSyent does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for BioSyent this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioSyent insiders have not sold or bought any company stock.Percentage Held by Institutions0.08% of the stock of BioSyent is held by institutions.Read more about BioSyent's insider trading history. Receive BIOYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOYF Stock News HeadlinesBioSyent to Present at Planet MicroCap Las VegasJune 15, 2026 | globenewswire.comBioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)May 19, 2026 | globenewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer. | Weiss Ratings (Ad)BioSyent Declares Second Quarter 2026 DividendMay 14, 2026 | globenewswire.comBioSyent Releases Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comBioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026May 7, 2026 | globenewswire.comBioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | globenewswire.comBioSyent Announces Grant of Restricted Share UnitsMarch 24, 2026 | globenewswire.comSee More Headlines BIOYF Stock Analysis - Frequently Asked Questions How have BIOYF shares performed this year? BioSyent's stock was trading at $9.52 at the beginning of 2026. Since then, BIOYF stock has increased by 25.7% and is now trading at $11.97. How do I buy shares of BioSyent? Shares of BIOYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/10/2026Next Earnings (Estimated)11/19/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:BIOYF CIKN/A Webwww.biosyent.com Phone(905) 206-0013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio58.82 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:BIOYF) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.